Veeva Systems jumps 6.1% as investors focus on upcoming earnings and fresh Vault CRM ...

Pharma-specific CRM momentum is good news for Veeva shareholders. It tells you something less comfortable about the broader CRM market.

Veeva's stock jumped 6% on the back of Vault CRM gaining ground globally — including a notable win with Merck KGaA. Investors are reading this as proof that vertical, purpose-built CRMs are winning against generic platforms. The story isn't really about life sciences. It's about what happens when a CRM is actually built around how a specific industry operates instead of asking the industry to bend around the software.

That's the part worth sitting with if you're in mid-market ops. The reason Veeva wins deals isn't price. It's that their platform reflects the actual workflows of the people using it — the compliance requirements, the customer data structures, the approval chains. Generic CRMs promise to do that too, usually through a consultant who charges $200/hour to map your process into a system that was never designed for it in the first place.

You've probably lived the other version of this story. A platform switch that was supposed to fix everything, a six-month implementation that stretched to twelve, and a team that still does half their work in spreadsheets because the CRM doesn't quite fit.

The lesson from Veeva's run isn't "buy life sciences software." It's that fit beats features every time — and most platforms are still selling you features.

#CRM #SalesOps #MidMarket #CRMStrategy #RevenueOperations

Original Source

... CRM globally, highlighting continued traction for the company's next-generation CRM platform. Also in late May, Veeva announced Merck KGaA ...